Pataer, Apar <br/><br/>
Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.  [electronic resource] 

 -  Cancer medicine  06 2018 
 - 2405-2414 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.1505  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>Rad51 Recombinase--genetics<br/>Survival Rate